Just three months have passed since the publication of my last article on Novartis AG (NYSE: NVS ), "Why Novartis Is Still a 'Buy' After 15% Surge."With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landsc ...